[Form 4] Organon & Co. Insider Trading Activity
Rhea-AI Filing Summary
Organon & Co. senior vice president and corporate controller Lynette Holzbaur reported equity compensation and related share activity. On March 31, 2026, she received grants of 75,125 and 41,736 Restricted Stock Units (RSUs), each RSU representing a contingent right to one share of Organon common stock. These RSUs will vest in three equal installments on March 31, 2027, 2028, and 2029.
The filing also shows vesting of earlier RSU awards from March 31, 2023 and March 31, 2025, with the remaining one‑third of those grants converting into common shares. As part of the vesting, 1,212 and 1,914 shares of common stock were withheld at $5.70 per share to satisfy tax obligations, a non‑market disposition. Following these transactions, Holzbaur holds 26,402.427 shares of Organon common stock directly. The activity reflects routine compensation grants, vesting, and tax withholding rather than open‑market buying or selling.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Restricted Stock Units | 75,125 | $0.00 | -- |
| Grant/Award | Restricted Stock Units | 41,736 | $0.00 | -- |
| Exercise | Restricted Stock Units | 4,252 | $0.00 | -- |
| Exercise | Restricted Stock Units | 6,715 | $0.00 | -- |
| Exercise | Common Stock | 4,252 | $0.00 | -- |
| Tax Withholding | Common Stock | 1,212 | $5.70 | $7K |
| Exercise | Common Stock | 6,715 | $0.00 | -- |
| Tax Withholding | Common Stock | 1,914 | $5.70 | $11K |
Footnotes (1)
- The price is the closing market price for Organon & Co. ("Organon") common stock on Monday, March 30, 2026, as required by the plan under which the Restricted Stock Units ("RSU") were awarded. On March 31, 2026, the Reporting Person was granted 75,125 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029. On March 31, 2026, the Reporting Person was granted 41,736 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029. Each RSU represents a contingent right to receive one share of Organon common stock. On March 31, 2023, the Reporting Person was granted 12,755 RSUs. Two-thirds of such RSUs previously vested, and the remaining one-third vested on March 31, 2026. On March 31, 2025, the Reporting Person was granted 20,147 RSUs. Two-thirds of such RSUs previously vested, and the remaining one-third vested on March 31, 2026.